... minute read
sponsor
This study is led by Haukeland University Hospital and is recruiting participants in Bergen and Ålesund.
COVID infections run with varying degrees of severity, but most people experience mild symptoms in the acute phase. Several studies have found that up to 30% of individuals who go through a COVID infection suffer from long-term effects, including difficulties with concentration, shortness of breath, and fatigue.
Choose your location
If you test positive for COVID, we invite you to participate in a research project testing the drug Paxlovid. This medication has been shown to shorten and alleviate the acute illness, and is already in use in Norway for patients at high risk of developing severe disease. The purpose is to investigate whether a five-day course of Paxlovid in the acute phase can prevent the development of long COVID.
If you’d like to join the study and it’s been less than five days since your COVID symptoms began, please click the contact button. You can reach out at any time—ideally as soon as possible.
You’re between 18 and 65 years old, and
You developed COVID symptoms within the last 5 days, and
You’ve confirmed it’s COVID with a positive rapid antigen test or PCR.
Pregnancy or breastfeeding. There is limited experience with Paxlovid in pregnant women, so pregnant individuals are excluded. You must use reliable contraception during the tablet course. Women of childbearing potential will be given a pregnancy test that must be negative before starting treatment. Breastfeeding women are also excluded.
Other serious illnesses. People with severe underlying conditions—especially those with impaired immune systems, organ transplants, or active cancer—may already need Paxlovid treatment, and it would be inappropriate to randomize them to placebo. Therefore, you cannot join the study if you have:
Severe immunodeficiency (e.g., congenital immunodeficiencies, untreated HIV, active cancer).
Ongoing treatment with strong immunosuppressive medications.
Use of certain medications. Some drugs interact adversely with Paxlovid. Study staff will review your current medications to determine if you’re eligible.
After you’ve expressed interest, study staff will contact you to provide more information about participation, schedule an inclusion interview, and arrange collection of the study medication. We will be happy to answer any questions you have about the study.
You will be asked to report symptoms and side effects daily for the first seven days, then weekly for four weeks, and again at 3, 6, 12, and 24 months. All reporting is done via electronic questionnaires sent to you by SMS.
Participation takes place in Bergen at the emergency clinic in Fana, and in Ålesund at the research unit at Ålesund Hospital. You will receive information about the address, parking, and appointment time by SMS.
Participants may withdraw from the study at any time by contacting the study coordinators.
The study is funded by the National Program for Clinical Treatment Research in Specialist Health Services (KLINBEFORSK). It is approved by the Regional Ethics Committee (REK no. 578741) and the Norwegian Medicines Agency.
Contact this trial today!
Have questions about our clinical trials or need more information on how to participate. Our team is here to provide you with all the details you need. Don’t hesitate to reach out to us today!
Thank you for exploring our trial!
We appreciate you taking the time to learn more. How can we assist you next?
Share this trial
Share this trial with someone who might find it helpful.
Contact the trial team
Let us know if you're interested in participating in this trial.
Download Page
Get a printable version to read later or share with your doctor.